PlexBio and Denka co-developed IntelliPlex™ SARS-CoV-2 Variant Analysis Kit (RUO) which can simultaneously identify the presence of SARS-CoV-2 virus and its variants in one reaction. Based on the variant classifications published by the United States Centers for Disease Control and Prevention (CDC), this kit was designed to identify the variants that were classified as Variants of Concern including B.1.1.7 (UK), B.1.351 (South Africa), P.1 (Brazil), and B.1.427/B.1.429 (California). Prof. Kazuhiro Tateda and Prof. Yoshikazu Ishii from the Department of Microbiology & Infectious Diseases at Toho University School of Medicine have evaluated and successfully verified that this kit can recognize these variants. This kit delivers test results within as little as 3.5 hours, whereas conventional methods would take two steps and approximately one day to obtain the same results. Since it has been known that some SARS-CoV-2 variants are more aggressive than the original strain of the virus and may escape from protective immune responses elicited by SARS-CoV-2 vaccinations to a certain extent, the demand for identifying SARS-CoV-2 variants is expected to grow quickly. IntelliPlex™ SARS-CoV-2 Variant Analysis Kit will be launched in Japan and globally in the next 1-2 months.
IntelliPlex™ SARS-CoV-2 Variant Analysis Kit is able to simultaneously detect SARS-CoV-2 virus and its multiple variants in one reaction utilizing our patented Code™ MicroDisc technology. Code™ MicroDiscs are made of silicon wafer and serve as message carriers in molecular analysis assay. Each Code™ MicroDisc carries a unique ID and is coupled with a probe designed to capture a specific target nucleic acid. This technology allows up to 85,000 unique Code™ MicroDisc IDs, enabling simultaneous analysis of multiple targets in one reaction. Any Code™ MicroDiscs that successfully capture targets will generate fluorescence signals, which along with their unique IDs can be recorded by an optical scanning system. The system can automatically process and analyze data and deliver a resulting report in 30 minutes. PlexBio and Denka will continue to closely monitor COVID19 pandemic, and revise the target virus variants to be analyzed by IntelliPlex™ SARS-CoV-2 Variant Analysis Kit whenever new virus variants arise. IntelliPlex™ SARS-CoV-2 Variant Analysis Kit provides an effective solution, and helps contain the spread of the virus.
For further information please email: email@example.com